TACTI-002: a phase II study of eftilagimod alpha (soluble LAG-3) & pembrolizumab in 2nd line PD-1/PD-L1 refractory metastatic NSCLC
Forster, M. Krebs, Matthew G Majem, M. Peguero, J. Clay, T. Felip, E. Iams, W. Roxburgh, P. Doger, B. Bajaj, P.
Forster, M.
Krebs, Matthew G
Majem, M.
Peguero, J.
Clay, T.
Felip, E.
Iams, W.
Roxburgh, P.
Doger, B.
Bajaj, P.
Citations
Altmetric:
Abstract
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Forster M, Krebs M, Majem M, Peguero J, Clay T, Felip E, et al. TACTI-002: A Phase II Study of Eftilagimod Alpha (Soluble LAG-3) & Pembrolizumab in 2nd line PD-1/PD-L1 Refractory Metastatic NSCLC. Journal of Thoracic Oncology. 2022 Sep;17(9):S395-S. PubMed PMID: WOS:000858678101128.